drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Humanized anti-CD19 monoclonal antibody (Monjuvi) optionally used post-infusion to ablate transferred CAR Tregs as a safety measure.
nci_thesaurus_concept_id
C95768
nci_thesaurus_preferred_term
Tafasitamab
nci_thesaurus_definition
An Fc engineered, humanized anti-CD19 monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities.Tafasitamab targets and binds to CD19, thereby depleting and eliminating CD19-expressing B-cells. The modified Fc region of XmAb5574 increases binding affinity to Fc-gamma receptors of effector cells and thereby enhances antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). CD19 is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.
drug_mesh_term
tafasitamab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Tafasitamab-cxix is a humanized anti-CD19 monoclonal antibody with an Fc-engineered region that enhances Fcγ receptor binding to promote antibody-dependent cellular cytotoxicity and phagocytosis, leading to depletion of CD19-expressing B cells (and any CD19-tagged engineered cells) for antineoplastic and immunomodulatory effects.
drug_name
Tafasitamab-cxix
nct_id_drug_ref
NCT05993611